New hope for tough lung cancers: drug combo shows promise

NCT ID NCT05941897

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study tests a combination of two drugs, ceralasertib and durvalumab, in adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors and control the disease. About 39 participants will receive the treatment, and researchers will measure how many respond and for how long.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 115533, Russia

  • Research Site

    Moscow, 125284, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Nizhny Novgorod, 603126, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Saint Petersburg, 198255, Russia

Conditions

Explore the condition pages connected to this study.